Patent · US Active

Methods for purifying trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol

US8383842B2 · kind B2 · utility

8Cited by

30References

35Claims

0Family size

Assignee

PURDUE PHARMA L.P. · US

Inventors

Arie Gutman · Haifa, IL
Gennady Nisnevich · Haifa, IL
Igor Rukhman · Nesher, IL
Boris Tishin · Haifa, IL
Marina Etinger · Nesher, IL
Irina Fedotev · Haifa, IL
Boris Pertsikov · Nesher, IL
Ram Khanolkar · West Greenwich, US

Key dates

Filing date	Nov 18, 2005
Grant date	Feb 26, 2013
Priority date	—
Expiry date	Feb 5, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D311/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(−)-Δ9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.